ClinicalTrials.gg
RecruitingNCT06640179HEALUpdated Jul 2, 2026

Feasibility and Plausible Effectiveness of a Lifestyle Intervention in Kidney Transplant Recipients (HEAL)

An interventional study of Standard medical care and Monitoring Contacts in Kidney Transplant, Overweight or Obese Adults and Glucose Control, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Overweight by University of Kansas Medical Center — 6 open to participants now, 6 under way, none of them phase 3. Overweight · University of Kansas Medical Center.

Planned enrollment
6th of 12
60 · median 52
Started
2024
with 2 others
No phase
12 of 13
5 open now
Registered
9th of 13
by date

Among the 13 studies in Overweight by University of Kansas Medical Center, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 9th registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

6 of the 13 studies in Overweight by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Overweight by University of Kansas Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether if it is feasible to implement a study of patients receiving kidney transplantation, to learn if these patients will complete selective outcomes measurements, and to examine if a lifestyle intervention may assist with preventing weight gain compared to standard medical care. The main questions it aims to answer are:

  • Is it feasible to recruit and retain patients who have undergone kidney transplantation into a study to compare standard medical care to standard medical care plus a lifestyle intervention focused on prevention of weight gain?
  • Will participants engage in the interventions and be compliant to the components of the interventions?
  • Will there be any difference between the interventions between the interventions for the occurrence of adverse events specific to kidney transplantation?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on preventing weight gain compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on body composition compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting glucose compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on fasting insulin compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on insulin sensitivity compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical function compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on health-related quality of life compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on changes in dietary intake compared to standard medical care alone?
  • Will there be initial effectiveness for the standard medical care plus a lifestyle intervention to have a better effect on physical activity and sedentary behavior compared to standard medical care alone?

Participants will:

  • Participants will continue with their standard medical care following kidney transplantation.
  • Participants only receiving standard medical care will also complete brief monitoring visits at week 6, 12, and 18.
  • Participants receiving the lifestyle intervention will attend weekly intervention sessions and will be recommended to modify their diet and physical activity behaviors in an effort to prevent weight gain.
  • Participants will complete outcome measurements as the start of the study and again after 6 months in the study.
  • After 6 months in the study, participants will also complete a brief intervention and answer other questions about their experience in the study.
03

Conditions studied

  • Kidney Transplant
  • Overweight or Obese Adults
  • Glucose Control

Keywords

  • kidney transplant
  • overweight
  • obesity
  • glucose control
  • weight control
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving a kidney transplant within the prior 3-5 months, with the transplant received from a deceased donor or living donor. NOTE: The patient will be eligible for randomization at 3 months following the kidney transplant, or at a subsequent time once clearance from the kidney transplant physician is given, provided that the time does not exceed 5 months following the kidney transplant.
  • Both males and females of all race/ethnic groups are eligible for participation in this study.
  • >=18 years of age.
  • (BMI) >22 kg/m2. There is no maximal BMI provided that the weight does not exceed the weight allowance of the dual-energy x-ray absorptiometer (DXA) that is used to assess body composition (maximal weight for the DXA is 350 pounds).
  • Ability to provide prior to participation in this study.
  • Ability to provide clearance from their kidney transplant physician to engage in the diet and physical activity components of the proposed intervention and to safely complete the proposed outcome measures.
  • Ability to walk for exercise.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breastfeeding, or reporting a planned pregnancy during the study period. Female participants of childbearing age who are not currently taking medication, are not , or have not been surgically sterilized will need to agree to use a double barrier method of contraception.
  • History of bariatric surgery.
  • Currently prescribed an anti-obesity medication.
  • Report current medical condition or treatment for a medical condition that could affect body weight. These may include the following: diabetes mellitus; hyperthyroidism; inadequately controlled hypothyroidism; chronic liver disease; cancer; gastrointestinal disorders including ulcerative colitis, Crohn's disease, or malabsorption syndromes; etc.
  • Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
  • Resting systolic blood pressure of >=160 mmHg or resting diastolic blood pressure of >=100 mmHg or not on a stable medical treatment to control hypertension (stable dose is defined as the same dose and type of medication for a period of at least 6 months).
  • Eating disorders that would contraindicate modifying eating or physical activity behaviors.
  • Alcohol or substance abuse.
  • Currently treated for psychological issues (i.e., depression, bipolar disorder, etc.) that is accompanied by the following: 1) not on a stable dose of medications for treatment within the previous 12 months, or 2) hospitalized for depression within the previous 5 years.
  • Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Standard Medical Care

    Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive brief conducts (\<10 minutes) from the research staff at weeks 6, 12, and 18.

    Other: Standard medical care · Behavioral: Monitoring Contacts

  • Experimental
    Standard Medical Care plus Lifestyle Intervention

    Standard Medical Care plus Lifestyle Intervention will continue to receive their regular standard clinical care and a behavioral intervention focused on dietary modification and physical activity for body weight regulation.

    Other: Standard medical care · Behavioral: Behavioral Sessions · Behavioral: Diet · Behavioral: Physical Activity

Interventions

  • OtherStandard medical care

    Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.

  • BehavioralMonitoring Contacts

    Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.

  • BehavioralBehavioral Sessions

    Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.

  • BehavioralDiet

    An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.

  • BehavioralPhysical Activity

    Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.

06

What researchers measure

Primary outcomes

  1. Body Weight

    Body weight will be assessed in duplicate using a calibrated digital scale to the nearest 0.1 kg.

    Time frame: 0 and 6 months

Secondary outcomes

  1. Body Mass Index

    Measurements of weight and height will be used to compute BMI (kg/m2).

    Time frame: 0 and 6 months

  2. Percent body fat

    Percent body fat will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  3. Body Fat Mass

    Body fat mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  4. Lean Body Mass

    Lean body mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  5. Bone mineral content

    Bone mineral content (grams) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  6. Waist Circumference

    Circumference measures of the waist taken horizontally at both the iliac crest and the umbilicus will be performed.

    Time frame: 0 and 6 months

  7. Hip Circumference

    Circumference measures of the hip taken horizontally at widest portion of the buttocks will be performed.

    Time frame: 0 and 6 months

  8. Resting blood pressure

    Resting blood pressure will be measured in duplicate following a 5-minute seated rest period using an automated measuring system.

    Time frame: 0 and 6 months

  9. Resting heart rate

    Resting heart rate will be measured following a 5-minute seated rest period using an automated measuring system.

    Time frame: 0 and 6 months

  10. Physical Function

    Physical function will be measured with a 400-meter walk test. The score will be the duration of time (minutes) it takes to complete the 400 meters.

    Time frame: 0 and 6 months

  11. Fasting glucose

    Fasting glucose will be measured from a blood sample collected after at least an 8-hour fasting period.

    Time frame: 0 and 6 months

  12. Fasting Insulin

    Fasting insulin will be measured from a blood sample collected after at least an 8-hour fasting period.

    Time frame: 0 and 6 months

  13. Insulin Resistance

    HOMA-IR will be used as a measure of Insulin resistance, which is computed from measures of fasting glucose and fasting insulin.

    Time frame: 0 and 6 months

  14. Kidney function

    Kidney function will be measured using glomerular filtration rate (GFR) measured from a blood sample after at least 8 hours of fasting.

    Time frame: 0 and 6 months

  15. Physical activity

    Physical activity will be assessed with the Paffenbarger questionnaire that queries on walking, flights of stairs climbed, and other sport, recreational, or leisure physic activity. Physical activity is represented by the total minutes of activity per week and estimated kilocalories of physical activity per week.

    Time frame: 0 and 6 months

  16. Physical Activity

    Physical activity is measured by the Global Physical Activity Questionnaire (GPAQ). This assesses time spent in recreational, occupational, household, and transportation physical activities and is represented as minutes per week.

    Time frame: 0 and 6 months

  17. Sedentary behavior

    Sedentary behavior is measured using an 8-item survey that is completed for weekdays and weekend days. Time spent in sedentary behavior is reported.

    Time frame: 0 and 6 months

  18. Energy Intake (Dietary Intake)

    Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using the Diet History Questionnaire (DHQ) developed by NCI. A higher score represents more calories eaten.

    Time frame: 0 and 6 months

  19. Weight Loss Strategies

    Weight Loss Strategies will be measured using the Weight Control Strategies Scale that includes 30 items. Each item is scored on a 0-4 scale and the scores across the 30 items are summed to provide an overall score, with a range for the total score being 0 to 120. A higher score is more favorable and represents engaging in more weight control strategies.

    Time frame: 0 and 6 months

  20. Weight Loss Strategies

    Weight Loss Strategies will be measured using the Eating Behavior Inventory that includes 26 items with each measured on a 5-point scale. The score from each item is summed for a total score, with the being 26-130. A higher score represents engaging in more appropriate weight loss strategies.

    Time frame: 0 and 6 months

  21. Health-Related Quality of Life

    Health-Related Quality of Life will be measured with a 36-item questionnaire (RAND 36-Item Health Survey) that includes 8 subscales of vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health or emotional wellbeing. All items are scored so that a high score defines a more favorable health state. The range of the final score for each subscale is 0-100.

    Time frame: 0 and 6 months

  22. Adverse and Serious Adverse Events

    Participants will be queried using a survey developed specifically for this study will be used to assess for adverse events and serious adverse events.

    Time frame: 0 and 6 months and at other times when reported by the participant

Other outcomes

  1. Medication History

    A questionnaire developed specifically for this study will be used to assessment medication history. The data collected include the type of medication, dose of medication, and frequency that the medication is taken, and what condition the medication is indicated to treat.

    Time frame: 0 and 6 months

  2. Lifestyle and Health History

    A questionnaire developed specifically for this study that is conducted as an interview will be used to assess lifestyle and health factors to describe the sample for this study. The score is either "yes" or "no" identifying the presences of a lifestyle or health factor.

    Time frame: 0 months (prior to randomization)

  3. Post-Intervention Qualitative Interview

    Each participant will undergo a qualitative interview in a face-to-face format to allow the investigators to better understand strengths, weaknesses, and barriers that will allow for further intervention refinement prior to proceeding a larger study.

    Time frame: 6 months

  4. Post-Intervention Qualitative Questionnaire

    Each participant will complete a questionnaire to allow the investigators to better understand strengths, weaknesses, and barriers that will allow for further intervention refinement prior to proceeding a larger study.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • HEAL Study · Contactjjakicic@kumc.edu · 913-588-5882
    • John M. Jakicic, PhD · Principal investigator
    • Diane Cibrik, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The summary data for each of the study outcomes and other additional demographic characteristics will be made available. The Study Protocol (which includes the statistical analysis plan), Manual of Procedures, Data Collection Forms, and a Data Dictionary to explain the data variables will be provided.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The data will be made available no later than the time of an associated publication of study outcomes or at the end of the performance period, whichever comes first. The data provided to the repository will be available indefinitely while that repository continues to exist.

Access criteria: The information included with the IPD will be made available to appropriate individuals only after the requester confirms their willingness to comply with an appropriate "Data Use Agreement" that complies with NIH policies, the policies of the institution where the study has been conducted, and the elements of informed consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 25 months is above that.

Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Dec 17, 2024
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06640179
Responsible party
John M. Jakicic, PhD (Professor, University of Kansas Medical Center) — Principal investigator
First posted
Oct 15, 2024
Start date
Dec 17, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

John M. Jakicic, PhD
Contact
jjakicic@kumc.edu
913-588-9078
John M. Jakicic, PhD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion